Cargando…
Real-world effects and adverse events of romosozumab in Japanese osteoporotic patients: A prospective cohort study
Real-world data on the new anti-sclerostin antibody drug, romosozumab, remain scarce. There is a strong need to accumulate and analyze data on romosozumab treatment for such conditions as osteoporosis. The purpose of this study was to investigate the therapeutic and adverse effects of romosozumab fo...
Autores principales: | Kobayakawa, Tomonori, Suzuki, Takako, Nakano, Masaki, Saito, Makoto, Miyazaki, Akiko, Takahashi, Jun, Nakamura, Yukio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085670/ https://www.ncbi.nlm.nih.gov/pubmed/33981812 http://dx.doi.org/10.1016/j.bonr.2021.101068 |
Ejemplares similares
-
Denosumab versus romosozumab for postmenopausal osteoporosis treatment
por: Kobayakawa, Tomonori, et al.
Publicado: (2021) -
Pentosidine and carboxymethyl-lysine associate differently with prevalent osteoporotic vertebral fracture and various bone markers
por: Nakano, Masaki, et al.
Publicado: (2020) -
Zinc Pharmacotherapy for Elderly Osteoporotic Patients with Zinc Deficiency in a Clinical Setting
por: Nakano, Masaki, et al.
Publicado: (2021) -
Efficacy and Safety of Oral Ibandronate versus Intravenous Zoledronic Acid on Bone Metabolism and Bone Mineral Density in Postmenopausal Japanese Women with Osteoporosis
por: Uehara, Masashi, et al.
Publicado: (2021) -
Serum bone alkaline phosphatase is a useful marker to evaluate lumbar bone mineral density in Japanese postmenopausal osteoporotic women during denosumab treatment
por: Nakamura, Yukio, et al.
Publicado: (2017)